Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

✍ Scribed by Kateřina Machová Poláková; Václava Polívková; Jana Rulcová; Hana Klamová; Tomáš Jurček; Dana Dvořáková; Daniela Žáčková; Zdeněk Pospíšil; Jiří Mayer; Jana Moravcová

• Book ID: 113616638
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 282 KB
• Volume: 38
• Category: Article
• ISSN: 0301-472X
• DOI: 10.1016/j.exphem.2009.10.003